Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

[1]  B. Garicochea,et al.  Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma , 2021, JAMA network open.

[2]  L. Becker,et al.  Isolation of polymorphonuclear neutrophils and monocytes from a single sample of human peripheral blood , 2021, STAR protocols.

[3]  S. Mustjoki,et al.  Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids , 2021, Journal for ImmunoTherapy of Cancer.

[4]  V. Cerullo,et al.  GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses , 2021, Molecular therapy. Methods & clinical development.

[5]  X. Zhang,et al.  Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic , 2020, Frontiers in Immunology.

[6]  Jun Yao,et al.  Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity , 2020, Cancer Research.

[7]  J. Jansen,et al.  Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies , 2020, mAbs.

[8]  J. Jansen,et al.  Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG , 2019, Front. Immunol..

[9]  T. K. van den Berg,et al.  FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils , 2019, Front. Immunol..

[10]  S. Goletz,et al.  Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts , 2018, Front. Immunol..

[11]  S. Thiel,et al.  Structure and activation of C1, the complex initiating the classical pathway of the complement cascade , 2017, Proceedings of the National Academy of Sciences.

[12]  J. Ravetch,et al.  The Role and Function of Fcγ Receptors on Myeloid Cells , 2016, Microbiology spectrum.

[13]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[14]  S. Lohse,et al.  Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing , 2015, Cancer Immunology Research.

[15]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[16]  William J Kelton,et al.  IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. , 2014, Chemistry & biology.

[17]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[18]  J. Weber,et al.  Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma , 2013, Clinical Cancer Research.

[19]  G. A. Lazar,et al.  Modulation of antibody effector function. , 2011, Experimental cell research.

[20]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[21]  C. Vajdic,et al.  Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.

[22]  J. Hsieh,et al.  Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  B. Liu,et al.  Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[25]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[26]  G. Blair,et al.  Restricted replication of human adenovirus type 5 in mouse cell lines. , 1989, Virus research.

[27]  Klaus Rajewsky,et al.  The half‐lives of serum immunoglobulins in adult mice , 1988, European journal of immunology.

[28]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.